[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"severe-malaria\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:severe-malaria":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,58,85,115],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100562326","phase-4-post-discharge-malaria-chemoprevention-implementation-trial-in-benin-100562326",false,"NCT06601712","Post-discharge Malaria Chemoprevention Implementation Trial in Benin","Delivery Strategies for Malaria Chemoprevention in the Post-discharge Management of Children Hospitalised With Severe Anaemia or Severe Malaria: a Cluster Randomised Controlled Implementation Trial in Benin","PDMC-SL","Inclusion Criteria:\n\n* Aged below 10 years of both sexes\n* Hospitalised with severe anaemia or severe malaria: Initially hospitalised with haemoglobin below 5.0 g\u002Fdl or PCV below 15%, or requirement for blood transfusion for other clinical reasons on or during admission to the hospital, or severe malaria, defined as a requirement for parenteral artesunate in the opinion of the treating clinician and the presence of microscopy or RDT confirmed Plasmodium infection\n\nExclusion Criteria:\n\n* Recognised specific other causes of severe anaemia (i.e., trauma, haematological malignancy, known bleeding disorders, such as haemophilia)\n* Sickle cell anaemia\u002Fsickle cell disease\n* Body weight below 5 kg\n* HIV infection and cotrimoxazole prophylaxis are not exclusion criteria","ALL","9 Years",{"count":20,"type":21},648,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The proposed research aims to conduct implementation trials in Benin, co-designed with national stakeholders, to evaluate different delivery strategies for optimizing health system delivery of post-discharge malaria chemoprevention (PDMC) drugs and adherence to PDMC. This chemoprevention strategy is effective in reducing hospital readmissions and deaths after discharge. However, there is no clear delivery platform for PDMC, and adherence to the 3-day dosing regimen, provided monthly three times after discharge, is a potential limitation. The current trial will provide evidence-based data on acceptability, feasibility, and cost-effectiveness to aid decision-makers. The evidence generated will be used to support the effective implementation and scale-up of PDMC in high malaria-endemic areas such as Benin.",[27,28],"Severe Malaria","Severe Anaemia",[30,31,32,33,34,35,36,37,38,39,40,41,42,43,44],"Children","Antimalarial","Prevention","Chemoprevention","Caregivers","Patient discharge","Health care providers","Health economics","Qualitative research","Feasibility","Cost-effectiveness","Benin","Artemisinins","School age","Pre-school","RECRUITING","2026-08-10",{"date":48,"type":49},"2026-08-12","ACTUAL",{"date":51,"type":49},"2025-07-02",{"date":53,"type":21},"2026-12-31",{"name":55,"class":56},"Institut de Recherche Clinique du Benin","OTHER",2,{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":15,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":65,"targetDuration":4,"studyType":22,"phases":67,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100564089","phase-4-pdmc-implementation-trial-in-kenya-100564089","NCT06624631","PDMC Implementation Trial in Kenya","Delivery Strategies for Malaria Chemoprevention in the Post-discharge Management of Children Hospitalised With Severe Anaemia or Severe Malaria: Cluster and Individually Randomised Controlled Implementation Trial and Economic Evaluation in Kenya","Inclusion Criteria:\n\nCLUSTERS\n\n* Health facilities with blood transfusion services offering in-patient care for children with severe anaemia and severe malaria.\n* \\>=40 children per year admitted with severe anaemia or severe malaria\n* Agreement to participate by facility management\n* Located in areas with moderate to high malaria transmission\n\nINDIVIDUAL PARTICIPANTS\n\n* Aged \\\u003C10 years of both sexes\n* Hospitalised with severe anaemia or severe malaria: Initially hospitalised with haemoglobin \\\u003C5.0 g\u002Fdl or PCV \\\u003C15%, or requirement for blood transfusion for other clinical reasons on or during admission to the hospital, or severe malaria, defined as a requirement for parenteral artesunate in the opinion of the treating clinician and\u002For the presence of microscopy or RDT confirmed Plasmodium infection\n\nExclusion Criteria:\n\nCLUSTERS\n\n\\- Health facilities without subservient lower-level health facilities\n\nINDIVIDUAL PARTICIPANTS\n\n* Recognised specific other causes of severe anaemia (i.e., trauma, haematological malignancy, known bleeding disorders, such as haemophilia)\n* Sickle cell anaemia\u002Fsickle cell disease\n* Body weight \\\u003C5 kg\n* HIV infection and cotrimoxazole prophylaxis are not exclusion criteria.",{"count":66,"type":21},600,[24],"The goal of this implementation trial is to evaluate at least two alternative delivery strategies and adherence support for malaria chemoprevention with dihydroartemisinin-piperaquine in the post-discharge management of children hospitalised with severe anaemia or severe malaria to optimise adherence in Kenya.\n\nThe actual interventions to be evaluated have been co-designed with national stakeholders during an initial formative research stage.",[27,70],"Severe Anemia",[30,31,32,33,34,35,72,37,38,39,73,74,42,43,44],"Healthcare providers","Cost effectiveness","Kenya","2025-11-18",{"date":77,"type":49},"2025-11-21",{"date":79,"type":49},"2025-09-05",{"date":81,"type":21},"2026-09-30",{"name":83,"class":56},"Liverpool School of Tropical Medicine",1,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":17,"minAge":93,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":22,"phases":97,"briefSummary":99,"conditions":100,"keywords":102,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":57},"100493924","platelet-directed-whole-blood-transfusion-strategy-for-malaria-100493924","NCT05711485","Platelet-Directed Whole Blood Transfusion Strategy for Malaria","Clinical and Translational Investigations of Severe Malaria Pathophysiology [Parent Study Protocol]","PLATFORM","Inclusion Criteria:\n\n* Age \\\u003C5 years\n* Platelet count ≤75,000\u002FuL\n* Hemoglobin \\>5 and ≤9 g\u002FdL\n* P. falciparum parasitemia ≥500 parasites\u002FuL\n* Diagnosis of severe malaria meeting World Health Organization (WHO) criteria\n* Ability and willingness of the legal guardian to comply with study protocol for the duration of the study\n* Residence within health clinic catchment area\n* Signed informed consent obtained from the parent or legal guardian of the participant\n\nExclusion Criteria:\n\n* Residence in foster care or children otherwise under government supervision\n* Residence outside the hospital catchment area, or plan to leave the area\n* Presence of any other condition or abnormality which, in the opinion of the investigator, would compromise the safety of the participant or the quality of the data\n* Any contraindication to whole blood transfusion","6 Months","59 Months",{"count":96,"type":21},132,[98],"NA","Open-label randomized controlled trial to test the effectiveness of whole blood transfusion for improving survival in children with severe malaria complicated by thrombocytopenia.",[27,101],"Thrombocytopenia",[103,104,105],"Malaria","Plasmodium falciparum","Zambia","2025-10-07",{"date":108,"type":49},"2025-10-09",{"date":110,"type":49},"2024-02-24",{"date":112,"type":21},"2028-05-31",{"name":114,"class":56},"Johns Hopkins Bloomberg School of Public Health",{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":22,"phases":125,"briefSummary":126,"conditions":127,"keywords":135,"overallStatus":155,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":84},"100564942","enhancing-pediatric-acute-care-through-adaptive-e-learning-and-in-person-skills-practice-in-tanzania-100564942","NCT06635733","Enhancing Pediatric Acute Care Through Adaptive E-Learning and In-Person Skills Practice in Tanzania","A Cluster Randomized Controlled Trial of the Pediatric Acute Care Education (PACE) Program Combining Adaptive E-Learning with In-Person Skills Practice in Tanzania","PACE","Inclusion Criteria:\n\n* Healthcare providers actively involved in pediatric care at one of the selected healthcare centers.\n* Completion of core Pediatric Acute Care Education (PACE) adaptive learning modules prior to study participation.\n* Willingness to participate in In-Person Skills Practice (ISP) sessions.\n* Ability to engage with either the Rhapsode Capable™ platform (intervention group) or paper-based ISP methods (control group).\n* Minimum proficiency in written and spoken English.\n\nExclusion Criteria:\n\n* Healthcare providers not involved in pediatric or newborn clinical care at the time of recruitment.\n* Providers unable or unwilling to attend ISP sessions facilitated by clinical champions.\n* Individuals with no prior engagement in the PACE program.\n* Providers with significant technological barriers that prevent the use of the Rhapsode Capable™ platform (for the intervention group only).",{"count":124,"type":21},100,[98],"The goal of this clinical trial is to evaluate whether the integration of in-person skills practice (ISP) with an adaptive e-learning platform can improve refresher learning progress (RLP) among healthcare providers in pediatric care settings in Tanzania.\n\nThe main questions it aims to answer are:\n\nCan healthcare providers who participate in ISP sessions facilitated by clinical champions achieve greater improvements in refresher learning progress (RLP)? Will providers in the intervention group demonstrate improved metacognition and practical skill performance compared to those in the control group? Researchers will compare healthcare providers using the ISP digital platform (Rhapsode Capable™) to providers using paper-based ISP to see if the digital platform results in significantly higher RLP and fewer skill-based errors.\n\nParticipants will:\n\nComplete adaptive e-learning modules focused on pediatric care topics (e.g., newborn resuscitation, severe malnutrition).\n\nParticipate in ISP sessions where clinical champions provide feedback and assess performance.",[128,129,27,130,131,132,133,134],"Newborn Resuscitation","Severe Malnutrition","Severe Pneumonia","Severe Dehydration","In-Service Training","Computer-Assisted Instruction","Simulation Training",[136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154],"Pediatric acute care","Newborn resuscitation","Severe malnutrition in children","Severe malaria treatment","Severe dehydration management","Pediatric pneumonia care","In-person skills practice (ISP)","Adaptive e-learning for healthcare providers","Clinical skills training in low-resource settings","Health provider education","Clinical champions","Tanzania healthcare providers","Pediatric emergency training","Blended learning in pediatric care","Refresher learning progress (RLP)","Cluster randomized controlled trial (RCT)","Rhapsode Capable™ platform","Skills assessment in pediatric care","Continuous professional development (CPD) for healthcare providers","NOT_YET_RECRUITING","2024-10-08",{"date":158,"type":49},"2024-10-10",{"date":160,"type":21},"2025-01-06",{"date":162,"type":21},"2026-12-01",{"name":164,"class":56},"Stanford University"]